Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries.

BACKGROUND Prostate-specific antigen (PSA) is the most important marker for prostate cancer, but PSA concentrations determined by various assays can differ significantly because of differences in specificity of the antibodies used. To identify epitopes recognized by various monoclonal antibodies (MAbs) to PSA, we have isolated peptides that react with the paratopes of these. METHODS Six anti-PSA MAbs representing three major epitope groups were screened with five cyclic phage display peptide libraries. After selection, the peptide sequences were determined by sequencing of the relevant part of viral DNA. Binding of the phage peptides to the MAbs was monitored by immunoassay. RESULTS For each MAb, several paratope-binding peptides with distinct sequence motifs were identified, but only approximately 10% showed similarity with the PSA sequence. Some of these correctly predicted the location of the epitopes. By sequential panning of the library with two closely related MAbs, we identified peptides reacting equally with both MAbs. When analyzed against a large panel of PSA MAbs, the peptides generally showed restricted specificity toward the MAb used for selection, but some peptides bound to several related MAbs. CONCLUSIONS Most of the cyclic peptides selected with PSA MAbs are specific for the MAb used for selection and do not resemble any sequence on the antigen. Peptides reactive with two MAbs recognizing the same epitope can be obtained by sequential panning. This method can be used to predict the location of some epitopes, but additional methods are needed to confirm the result.

[1]  L. Kuhn,et al.  The role of structure in antibody cross-reactivity between peptides and folded proteins. , 1998, Journal of molecular biology.

[2]  E. Diamandis,et al.  Characterization of the BRCA1-like immunoreactivity of human seminal plasma. , 1999, Urology.

[3]  U. Stenman,et al.  Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. , 1999, Clinical chemistry.

[4]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[5]  H. Lilja,et al.  Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. , 1995, Clinical chemistry.

[6]  Jens Schneider-Mergener,et al.  Crystallographic Analysis of Anti-p24 (HIV-1) Monoclonal Antibody Cross-Reactivity and Polyspecificity , 1997, Cell.

[7]  R. Ekins.  Immunoassay standardization. , 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[8]  H. Rittenhouse,et al.  Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1. , 1999, Urology.

[9]  G. Deléage,et al.  Anti-free prostate-specific antigen monoclonal antibody epitopes defined by mimotopes and molecular modeling. , 1999, Clinical chemistry.

[10]  U. Stenman,et al.  Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. , 2000, European journal of biochemistry.

[11]  M. Vihinen,et al.  Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling , 1998, Protein science : a publication of the Protein Society.

[12]  M T Palmiter,et al.  The antigen-antibody reaction. V. A quantitative theory of antigen-antibody reactions which allows for heterogeneity of antibodies. , 1965, Journal of theoretical biology.

[13]  R. Wolfert,et al.  Western Blotting Analysis of Antibodies to Prostate-Specific Antigen: Cross-Reactivity with Human Kallikrein-2 , 1999, Tumor Biology.

[14]  S. Barni,et al.  Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. , 1997, European urology.

[15]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[16]  P. Wingo,et al.  Cancer statistics, 1995 , 1995, CA: a cancer journal for clinicians.

[17]  G G Klee,et al.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.

[18]  U. Stenman,et al.  Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. , 1993, Clinical chemistry.

[19]  U. Stenman,et al.  Reactivity of 77 Antibodies to Prostate-Specific Antigen with Isoenzymes and Complexes of Prostate-Specific Antigen , 1999, Tumor Biology.

[20]  A. Kramer,et al.  Molecular Basis for the Binding Promiscuity of an Anti-p24 (HIV-1) Monoclonal Antibody , 1997, Cell.

[21]  L. Bellanger,et al.  Epitope Mapping of 53 Antibodies against Prostate-Specific Antigen , 1999, Tumor Biology.

[22]  D. Chargelegue,et al.  A Peptide Mimic of a Protective Epitope of Respiratory Syncytial Virus Selected from a Combinatorial Library Induces Virus-Neutralizing Antibodies and Reduces Viral Load In Vivo , 1998, Journal of Virology.

[23]  P. Carpenter,et al.  A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. , 2001, Cancer research.

[24]  R. Vessella,et al.  Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies. , 1997, Clinical chemistry.

[25]  R A Sayle,et al.  RASMOL: biomolecular graphics for all. , 1995, Trends in biochemical sciences.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[27]  U. Stenman,et al.  Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. , 1998, Clinical chemistry.

[28]  David J. Newman,et al.  Principles and Practice of Immunoassay , 1991, Palgrave Macmillan UK.

[29]  U. Stenman,et al.  Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. , 1995, Clinical chemistry.

[30]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[31]  M. Atassi,et al.  Immunochemistry of Proteins , 1979, Springer US.

[32]  U. Stenman,et al.  Characterization of monoclonal antibodies for prostate-specific antigen and development of highly sensitive free prostate-specific antigen assays. , 1999, Clinical chemistry.

[33]  H. Lilja,et al.  Molecular cloning of human prostate specific antigen cDNA , 1987, FEBS letters.

[34]  O. Nilsson,et al.  Summary Report of the TD-3 Workshop: Characterization of 83 Antibodies against Prostate-Specific Antigen , 1999, Tumor Biology.

[35]  E. Getzoff,et al.  A structural model for the prostate disease marker, human prostate‐specific antigen , 1994, Protein science : a publication of the Protein Society.

[36]  F. Felici,et al.  Selection of biologically active peptides by phage display of random peptide libraries. , 1996, Current opinion in biotechnology.

[37]  O. Nilsson,et al.  Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA. , 1997, British Journal of Cancer.

[38]  J. Leinonen,et al.  Complex formation between PSA isoenzymes and protease inhibitors. , 1996, The Journal of urology.

[39]  G. Reed,et al.  Sequences of antigenic epitopes of streptokinase identified via random peptide libraries displayed on phage. , 1997, Journal of molecular biology.

[40]  B. Morris,et al.  Primary structure of a human glandular kallikrein gene. , 1987, DNA.

[41]  K. Pettersson,et al.  Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with a . 1-Antichymotrypsin , 2004 .

[42]  D. Wishart,et al.  Epitope mapping of prostate-specific antigen with monoclonal antibodies. , 1996, Clinical chemistry.

[43]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[44]  F. Richards,et al.  Combining Regions of Antibodies , 1979 .

[45]  G. Paradis,et al.  High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate‐specific antigen , 1988, FEBS letters.

[46]  N. Greenspan,et al.  Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[48]  R. Wolfert,et al.  Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. , 1998, Urology.